A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

[1] Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[2] Miller KD(2017)Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis Jpn J Clin Oncol 47 1-8

[3] Jemal A(1999)Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1-7

[4] Furuse J(2016)Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions Expert Rev Anticancer Ther 16 523-530

[5] Gemma A(2017)Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials Front Oncol 7 149-6728

[6] Ichikawa W(2002)Identification and characterization of the UL56 gene product of herpes simplex virus type 2 J Virol 76 6718-1084

[7] Okusaka T(2006)Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer Ann Surg Oncol 13 1078-989

[8] Seki A(2004)Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer Ann Oncol 15 988-1117

[9] Ishii T(2006)Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma Acta Otolaryngol 126 1115-175

[10] Sener SF(2011)A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer Cancer Gene Ther 18 167-1061

[1] Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[2] Miller KD(2017)Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis Jpn J Clin Oncol 47 1-8

[3] Jemal A(1999)Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1-7

[4] Furuse J(2016)Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions Expert Rev Anticancer Ther 16 523-530

[5] Gemma A(2017)Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials Front Oncol 7 149-6728

[6] Ichikawa W(2002)Identification and characterization of the UL56 gene product of herpes simplex virus type 2 J Virol 76 6718-1084

[7] Okusaka T(2006)Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer Ann Surg Oncol 13 1078-989

[8] Seki A(2004)Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer Ann Oncol 15 988-1117

[9] Ishii T(2006)Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma Acta Otolaryngol 126 1115-175

[10] Sener SF(2011)A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer Cancer Gene Ther 18 167-1061